Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal
Bio‑Thera Solutions Inc. (SHA: 688177) announced a licensing agreement granting Gedeon Richter Plc. commercialization rights...
Biosimilars
Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration (FDA)...
Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that BA6101, its biosimilar version of Amgen’s...
Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first commercial batch of its...
Henlius HLX14 Denosumab Biosimilar NDA Accepted by China CDE
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the National Medical Products Administration’s Center for...
Boan Biotech’s Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that its self‑developed Aflibercept Intravitreal Injection (Boyoujing)...
Henlius’ POHERDY (HLX11) Receives Full FDA Approval for All Pertuzumab Indications
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its pertuzumab biosimilar POHERDY (clinical name HLX11)...
EirGenix Secures $152 M Licensing Deal for EG1206A Breast‑Cancer Biosimilar from Sandoz
EirGenix Inc. (TPE: 6589) announced a second, worldwide exclusive licensing agreement with Sandoz AG (SWX:...
Shanghai Henlius Biotech Secures UK MHRA Approval for Denosumab Biosimilars BILDYOS & BILPREVDA
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the United Kingdom’s Medicines and Healthcare Products...
FDA Issues Draft Guidance to Accelerate Biosimilar Development and Cut Costs
The U.S. Food and Drug Administration (FDA) released a draft guidance titled “Scientific Considerations in...
Henlius Organon Secure EU Marketing Approval for BILDYOS and BILPREVDA Denosumab Biosimilars
Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon (NYSE: OGN) announced that the European Commission...
Bio-Thera Partners with Jamjoom Pharma to Launch BAT2306 Biosimilar in MENA
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) announced on September 15, 2025, that it has entered...
Taiji Group Secures NMPA Approval to Begin Clinical Trials of Semaglutide Biosimilar
China‑based Chongqing Taiji Industry (Group) Co., Ltd. (Taiji Group, SHA: 600129) announced that its semaglutide...
Shanghai Henlius Biotech Secures FDA IND Approval for HLX17, a Pembrolizumab Biosimilar
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration (FDA)...
Fosun Secures FDA Approval for Two Denosumab Biosimilar Formulations
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that the Biologics License...
Mabwell Secures First Overseas Approval for Denosumab Biosimilars in Pakistan
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the Drug Regulatory Authority of Pakistan...
Bio-Thera Adjusts BAT3306 Clinical Study to Meet Regulatory Standards
On August 21, 2025, China-based Bio-Thera Solutions, Ltd. (SHA: 688177) announced a strategic adjustment to...
Henlius Biotech’s HLX04-O Accepted by NMPA for Wet AMD Treatment
Shanghai Henlius Biotech Inc. (HKG: 2696) announced on August 13, 2025, that the marketing authorization...
Shandong Boan’s Boyouping Receives NMPA Approval for Type 2 Diabetes Treatment
Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced on August 8, 2025, that its self-developed...
Mabwell Signs Licensing Agreement with Unilab for Denosumab Biosimilars in the Philippines
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced a licensing agreement with Unilab, Inc.,...